HOME >> BIOLOGY >> NEWS
First discovery of an immune system counter attack in the virus wars

In their endless war against the immune system, viruses rapidly evolve new evasive strategies. But scientists have uncovered the first genetic evidence of counter attack by the beleaguered immune defenses: Immune proteins that viruses once exploited have apparently evolved the ability to call in attacks against their former exploiters.

This case of immune proteins turning the table on the invaders may be quite common the researchers think, since genetic evolution appears to race fastest where the fighting is fiercest in the give-and take battle between pathogens and the receptors that encounter them on the surface of immune cells.

The research led by UCSF scientists will be published online April 11 by SCIENCE (http://www.sciencexpress.org) and will appear in the journal several weeks later.

The discovery comes from a study of a strain of mice able to resist infection by a virus known as murine cytomegalovirus, or MCMV, related to the human cytomegalovirus, smallpox virus, Epstein-Barr and other human viruses.

The key finding involves changes that have apparently occurred in an inhibitory receptor a protein on the surface of natural killer, or NK, immune cells that normally prevents killer cells from launching an autoimmune attack against ones own tissues. The inhibitory receptor sends a stop signal when it recognizes and binds to self molecules on normal, healthy tissue, and the signal reigns in the killer cells. Other researchers have found evidence that viruses have evolved the ability to make decoys of these self molecules, thereby triggering the stop signal and protecting themselves from immune attack.

The new research shows that in some strains of mice resistant to MCMV, the immune system has adapted by retaining the ability to bind to the virus signal but losing the ability to bind to self molecules. As a result, the former inhibitory receptor has become an activating re
'"/>

Contact: Wallace Ravven
wravven@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
11-Apr-2002


Page: 1 2 3

Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
8. First target for childhood malaria vaccine
9. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
10. First flavors form a lasting impression
11. STN International launches Derwent World Patents Index First View

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First discovery immune system counter attack the virus wars

(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
(Date:7/3/2015)... Forskare kan ansöka ... http://www.openinnovationinscience.at till det återkommande utbildningsprogrammet "Lab ... i Wien .  ... forskare och vetenskapsmän som genomfördes av Ludwig ... utmaningar bristen på incitament för att undersöka ...
(Date:7/2/2015)... GLEN ELLYN, Ill. , July 2, 2015 /PRNewswire-USNewswire/ ... and Colton Eakins are gaining invaluable real-world ... Institute of Technology this summer. The students ... Dr. Jeff Wereszczynski,s research group at IIT. ... Professors Dr. Tom Carter , Physics; Dr. ...
(Date:7/1/2015)... ... 2015 , ... It is now possible to separate two common disorders: post-traumatic ... tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and ... is believed to be the largest brain imaging study ever, will be published on ...
(Date:7/1/2015)... 2015   Neuraltus Pharmaceuticals, Inc. , a privately-held ... drugs to treat neurodegenerative diseases such as amyotrophic ... G. Miller , M.D., Director of the Forbes Norris ... Medical Center in San Francisco, has been awarded a ... to help fund a Phase 2 clinical study ...
Breaking Biology Technology:Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3COD Students Participate in Prestigious Summer Internships 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
Cached News: